Since both preclinical and clinical data (18, 41) indicate that GSK2879552 is a strong antitumor reagent with acceptable tolerability and safety profile in patients with advanced cancers including small-cell lung cancer (SCLC) and AML, we propose that inhibiting LSD1 by GSK2879552 could be a potential therapeutic option for patients with BCa. The gene discussed is KDM1A; the disease is small cell lung carcinoma.